Sangamo Therapeutics' (SGMO) "Buy" Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Sangamo Therapeutics (NASDAQ:SGMO - Free Report) in a research note issued to investors on Wednesday morning, Benzinga reports. The brokerage currently has a $5.00 price objective on the biopharmaceutical company's stock.

A number of other equities analysts also recently issued reports on SGMO. StockNews.com initiated coverage on Sangamo Therapeutics in a research note on Saturday, April 27th. They set a sell rating for the company. Royal Bank of Canada restated a sector perform rating and set a $2.00 target price on shares of Sangamo Therapeutics in a research report on Thursday, March 14th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of Hold and an average price target of $5.67.

Sangamo Therapeutics Stock Performance

Sangamo Therapeutics stock traded up $0.01 during mid-day trading on Wednesday, reaching $0.58. 1,915,808 shares of the company were exchanged, compared to its average volume of 2,121,217. The firm has a market cap of $120.38 million, a PE ratio of -0.31 and a beta of 1.40. The firm's 50-day simple moving average is $0.62 and its two-hundred day simple moving average is $0.59. Sangamo Therapeutics has a twelve month low of $0.29 and a twelve month high of $1.67.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last posted its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.05). Sangamo Therapeutics had a negative net margin of 1,749.06% and a negative return on equity of 182.55%. The firm had revenue of $0.48 million during the quarter, compared to analysts' expectations of $8.51 million. During the same quarter last year, the business earned $0.12 earnings per share. As a group, equities research analysts anticipate that Sangamo Therapeutics will post -0.54 EPS for the current year.

Institutional Investors Weigh In On Sangamo Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in SGMO. Vanguard Personalized Indexing Management LLC purchased a new stake in shares of Sangamo Therapeutics in the third quarter valued at $26,000. Mackenzie Financial Corp raised its position in shares of Sangamo Therapeutics by 72.4% in the fourth quarter. Mackenzie Financial Corp now owns 73,799 shares of the biopharmaceutical company's stock valued at $40,000 after buying an additional 31,003 shares during the last quarter. State Board of Administration of Florida Retirement System lifted its stake in shares of Sangamo Therapeutics by 61.1% during the first quarter. State Board of Administration of Florida Retirement System now owns 62,345 shares of the biopharmaceutical company's stock valued at $42,000 after buying an additional 23,650 shares during the period. SG Americas Securities LLC grew its stake in Sangamo Therapeutics by 255.2% in the 3rd quarter. SG Americas Securities LLC now owns 88,542 shares of the biopharmaceutical company's stock worth $53,000 after acquiring an additional 63,612 shares during the period. Finally, Golden State Equity Partners lifted its stake in shares of Sangamo Therapeutics by 21.0% during the 4th quarter. Golden State Equity Partners now owns 201,225 shares of the biopharmaceutical company's stock worth $109,000 after purchasing an additional 34,960 shares during the period. 56.93% of the stock is currently owned by hedge funds and other institutional investors.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.